Bengt Westermark
Direktor/Vorstandsmitglied bei MEDIVIR AB
Profil
Mr. Bengt Westermark is an Independent Director at Medivir AB, a Professor at University of Uppsala, a Member at European Molecular Biology Organization, a Member at Royal Society of Sciences, a Member at Royal Swedish Academy of Sciences and a Member at The European Academy of Cancer Sciences.
He is on the Board of Directors at Medivir AB.
Mr. Westermark was previously employed as a Chairman-Research Board by The Swedish Cancer Society.
He also served on the board at Hamlet BioPharma AB.
Aktive Positionen von Bengt Westermark
| Unternehmen | Position | Beginn |
|---|---|---|
| MEDIVIR AB | Direktor/Vorstandsmitglied | 01.01.2017 |
| University of Uppsala | Corporate Officer/Principal | 01.01.1986 |
Royal Swedish Academy of Sciences
 Royal Swedish Academy of Sciences Miscellaneous Commercial ServicesCommercial Services The Royal Swedish Academy of Sciences provides research and development services on sciences. The non-profit company is based in Stockholm, Sweden. | Corporate Officer/Principal | - |
| European Molecular Biology Organization | Corporate Officer/Principal | - |
| Royal Society of Sciences | Corporate Officer/Principal | - |
The European Academy of Cancer Sciences
 The European Academy of Cancer Sciences Miscellaneous Commercial ServicesCommercial Services The European Academy of Cancer Sciences is an independent advisory body of medical specialists and researchers. The Swedish company's mission is to create a continuum of cancer research, from basic research to evidence-based cancer care and prevention. The private company provides evidence-based advice to inform policy and organize their work through scientific committees gathered around priority areas across the cancer spectrum. The Academy has consulted a wide range of cancer research, policy, and care specialists and patient organizations to formulate consensus advice to the cancer mission board. The company reached the consensus view that a comprehensive translational cancer research approach that is focused on personalized/precision medicine and that covers the entire cancer research, cancer care, and prevention continuum has the potential to achieve in 2030 the goal of a 10-year cancer-specific survival for 75%% of the patients diagnosed with cancer in EU member states with a well-developed healthcare system. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Bengt Westermark
| Unternehmen | Position | Ende |
|---|---|---|
| MEDIVIR AB | Direktor/Vorstandsmitglied | 05.05.2021 |
| The Swedish Cancer Society | Corporate Officer/Principal | 01.01.2013 |
| HAMLET PHARMA AB (PUBL) | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| MEDIVIR AB | Health Technology |
| HAMLET PHARMA AB (PUBL) | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Royal Swedish Academy of Sciences
Royal Swedish Academy of Sciences Miscellaneous Commercial ServicesCommercial Services The Royal Swedish Academy of Sciences provides research and development services on sciences. The non-profit company is based in Stockholm, Sweden. | Commercial Services |
| The Swedish Cancer Society | |
| European Molecular Biology Organization | |
| Royal Society of Sciences | |
The European Academy of Cancer Sciences
The European Academy of Cancer Sciences Miscellaneous Commercial ServicesCommercial Services The European Academy of Cancer Sciences is an independent advisory body of medical specialists and researchers. The Swedish company's mission is to create a continuum of cancer research, from basic research to evidence-based cancer care and prevention. The private company provides evidence-based advice to inform policy and organize their work through scientific committees gathered around priority areas across the cancer spectrum. The Academy has consulted a wide range of cancer research, policy, and care specialists and patient organizations to formulate consensus advice to the cancer mission board. The company reached the consensus view that a comprehensive translational cancer research approach that is focused on personalized/precision medicine and that covers the entire cancer research, cancer care, and prevention continuum has the potential to achieve in 2030 the goal of a 10-year cancer-specific survival for 75%% of the patients diagnosed with cancer in EU member states with a well-developed healthcare system. | Commercial Services |
